.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,160,726

« Back to Dashboard

Details for Patent: 5,160,726

Title: Filter sterilization for production of colloidal, superparamagnetic MR contrast agents
Abstract:An improvement is provided to a method for obtaining an in vivo MR image of an organ or tissue of an animal or human subject, of the type including administering to the subject as a contrast agent to enhance such MR image an effective amount of a colloid including superparamagnetic metal oxide particles dispersed in a physiologically acceptable carrier. In accordance with the improvement, the method includes preparing the colloid in a manner that provides a reduction in toxicity in comparison with that associated with administration of the colloid after terminal sterilization. The improvement may include sterilizing the colloid by filtration. In an additional embodiment, the colloid may be sterilized by filtration and preserved by lyophilization. The colloid may be lyophilized in the presence of a compatible excipient. The excipient utilized may include a dextran or a citrate anion. Other embodiments include related compositions and methods.
Inventor(s): Josephson; Lee (Arlington, MA), Groman; Ernest V. (Brookline, MA), Palmacci; Stephen (Walpole, MA)
Assignee: Advanced Magnetics Inc. (Cambridge, MA)
Filing Date:Feb 05, 1991
Application Number:07/650,957
Claims:1. An improved method, for obtaining an in vivo MR image of an organ or tissue of an animal or human subject, of the type including administering to such subject as a contrast agent to enhance such MR image an effective amount of a colloid including superparamagnetic metal oxide particles dispersed in a physiologically acceptable carrier, in such a manner as to provide a reduction in toxicity in comparison with that associated with administration of the colloid after terminal sterilization, wherein the improvement comprises preparing and sterilizing the colloid in a manner that avoids subjecting the resulting active ingredient to heat stress.

2. A method according to claim 1, wherein preparing and sterilizing the colloid includes the step of sterilizing the colloid by filtration.

3. A method according to claim 2, wherein the step of sterilizing the colloid by filtration includes the step of removing materials from the colloid that would otherwise clog the filter used to achieve sterilization.

4. A method according to claim 3, wherein the step of sterilizing the colloid by filtration includes passing the colloid through successively smaller pore size filters, the smallest pore size filter being not greater than approximately 220 nm.

5. A method according to claim 3, wherein the step of sterilizing the colloid by filtration includes using a magnetic filter to selectively remove larger particles.

6. A method according to claim 3, wherein the step of sterilizing the colloid by filtration includes using column chromatography to selectively remove larger particles from the colloid.

7. A method according to claim 3, wherein the step of sterilizing the colloid by filtration includes centrifuging the colloid and passing the supernatant through a filter having a pore size not greater than approximately 220 nm.

8. A method according to claim 1, wherein the metal oxide particles comprise crystals, each crystal about 10 to about 500 angstroms in diameter and having an overall diameter of about 10 to not more than about 4000 angstroms as measured to light scattering.

9. A method according to claim 2, wherein the metal oxide particles comprise crystals, each crystal about 10 to about 500 angstroms in diameter and having an overall diameter of about 10 to not more than about 4000 angstroms as measured to light scattering.

10. A method according to claim 3, wherein the metal oxide particles comprise crystals, each crystal about 10 to about 500 angstroms in diameter and having an overall diameter of about 10 to not more than about 4000 angstroms as measured to light scattering.

11. A method according to claim 1, wherein the metal oxide particles are associated with a macromolecular substance.

12. A method according to claim 2, wherein the metal oxide particles are associated with a macromolecular substance.

13. A method according to claim 3, wherein the metal oxide particles are associated with a macromolecular substance.

14. A method according to claim 1, wherein the colloid includes dextran magnetite.

15. A method according to claim 2, wherein the colloid includes dextran magnetite.

16. A method according to claim 3, wherein the colloid includes dextran magnetite.

17. A method according to claim 2, further comprising lyophilizing the filter-sterilized colloid.

18. A method according to claim 17, wherein the filter-sterilized colloid is lyophilized in the presence of a compatible excipient.

19. A method according to claim 18, wherein the excipient includes one or more compositions selected from the group consisting of a dextran and a citrate anion.

20. A method according to claim 19, further comprising reconstituting the lyophilized colloid with an aqueous composition.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc